GE Vernovaの空売り状況は、投資家がGE Vernovaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

GE Vernova (NYSE:GEV) 株価情報, 空売り情報

GE VERNOVA INC

GE Vernova

GE Vernov

GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.

Equities

News

Markets

Media

Trading Ideas

BBWI

BLDR

EPAM

FSLR

INTC

LULU

NVDA

SMCI

今年の株式市場は、インフレーション圧力の緩和、企業の強い利益、およびAI（人工知能）技術の潜在的な利益に対する楽観的な期待を受けて、連邦準備制度が9月に金利を引き下げるとの期待が高まっています。

S&amp;P500上半期終了も史上最高値を更新せず

Movers

DELL

FWONA

NICE

過去1週間でこれらの10つの大型株は最も悪いパフォーマンスを発揮しました。それで、あなたのポートフォリオに含まれていますか？

大型株パフォーマンス下落　NIOを筆頭に

GE Vernova Inc

GENERAL ENTERPRISE VENTUR by GENERAL ENTERPRISE VENTURES INC.

General Enterprise Ventures Inc

Gevo Inc

In the preceding three months, 10 analysts have released ratings for Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Agree Realty, revealing an average target of $78.6, a high estimate of $84.00, and a low estimate of $74.00. Observing a 0.7% increase, the current average has risen from the previous average price target of $78.05. 
<img src="https://www.benzinga.com/files/images/story/2025/1743703251_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Agree Realty's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$74.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$79.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$81.00</td>
<td>$81.50</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$79.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$79.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Agree Realty. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Agree Realty compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Agree Realty's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Agree Realty analyst ratings.</a>
<h2>Discovering Agree Realty: A Closer Look</h2>
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.
<h3>A Deep Dive into Agree Realty's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Agree Realty's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.49% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: Agree Realty's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 26.92% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Agree Realty's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.83%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Agree Realty's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.52%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Agree Realty's debt-to-equity ratio is below the industry average. With a ratio of 0.53, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Agree Realty: Insights From 10 Analyst Reviews

New Fortress Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NYSE">NFE</a>) short percent of float has risen 22.73% since its last report. The company recently reported that it has 38.83 million shares sold short, which is 26.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>New Fortress Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743703253_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for New Fortress Energy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing New Fortress Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, New Fortress Energy's peer group average for short interest as a percentage of float is 3.44%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is New Fortress Energy Gaining or Losing Market Support?

Apple's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NYSE">AAPL</a>) short percent of float has fallen 4.44% since its last report. The company recently reported that it has 129.68 million shares sold short, which is 0.86% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.29 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Apple Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743703247_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Apple has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Apple's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Apple's peer group average for short interest as a percentage of float is 8.98%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

AAPL

What Does the Market Think About Apple?

In the current market session, Ovintiv Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) share price is at $40.84, after a 7.48% drop. Over the past month, the stock increased by 4.79%, but over the past year, it actually fell by 27.97%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1743703226_0.png" alt="Past Year Chart" />

<h3>Comparing Ovintiv P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Ovintiv has a lower P/E than the aggregate P/E of 30.02 of the Oil, Gas &amp; Consumable Fuels industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743703226_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Ovintiv Inc's Price Over Earnings

In the last three months, 8 analysts have published ratings on Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Altimmune, revealing an average target of $16.0, a high estimate of $25.00, and a low estimate of $12.00. Observing a 1.85% increase, the current average has risen from the previous average price target of $15.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1743703213_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Altimmune's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Annabel Samimy</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Altimmune. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Altimmune compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Altimmune's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Altimmune analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Altimmune</h2>
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
<h3>Financial Milestones: Altimmune's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Altimmune's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -86.49% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Altimmune's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -463600.0%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Altimmune's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -18.05%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Altimmune's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -16.14%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Assess Altimmune: What You Need To Know

WIIM

ABTS

ADBE

ADSK

ALKT

ASAN

AUID

AVPT

BILL

BRZE

BTBT

BTDR

BTOG

CFLT

CIFR

CRWD

CVLT

CYBR

DDOG

DOCU

ESTC

FROG

FRSH

FTNT

GTLB

HUBS

INTA

INTU

KVYO

NCNO

ORCL

PANW

PATH

PEGA

QTWO

QUBT

RBRK

SEMR

SOUN

WDAY

Shares of software companies are trading lower as markets react to President Trump's announcement of sweeping tariffs.

Goldman Sachs analyst Susan Maklari maintains Worthington Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) with a Sell and raises the price target from $39 to $44.

Price Target

Goldman Sachs Maintains Sell on Worthington Enterprises, Raises Price Target to $44

Decentralized exchange aggregator ParaSwap has rebranded to Velora, unveiling a major technical shift toward intents-based trading—a model that departs from traditional single-block execution by allowing traders to express desired outcomes rather than fixed transaction paths.
The shift, announced Thursday, is built on the release of Velora's Delta v2.5 infrastructure, introducing a competitive agent model where solvers and market makers vie to fulfill user-defined trading goals. 
This marks a move away from the legacy aggregator model that has underpinned decentralized finance since its early growth.
At its core, intents-based trading enables users to specify conditions or outcomes—such as a desired price or action—without defining every technical step of the trade. 
Competing agents then optimize execution within those parameters. 
This opens up use cases like on-chain limit orders and cross-chain swaps, previously constrained by smart contract rigidity and single-block processing limitations.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44630530/bondex-web3-app-surpasses-5m-downloads-amid-growing-interest-in-decentralized-career-platforms">Bondex Web3 App Surpasses 5M Downloads Amid Growing Interest In Decentralized Career Platforms</a>
"Legacy aggregators are limited by rigid smart contracts and same-chain execution," said Velora founder Mounir Benchemled. "Intents offer greater flexibility, giving users more control over how and when their trades are executed."
According to a press release, Velora also introduces features like Instant Cross-Chain Swaps—which aim to eliminate delays and reduce bridging risks—and a Super Hooks system, allowing users to automate complex trading workflows, such as collateral swaps or liquidity pool management.
Another feature is chain abstraction, which allows users to initiate and complete trades across multiple blockchains without manual bridging. 
This is central to Velora's approach to improving speed, flexibility, and overall efficiency in decentralized markets.
While the concept of intents-based DEXs has gained attention across DeFi, practical implementations have lagged. 
Velora positions its infrastructure as a more production-ready version, built for both performance and usability. 
The system is modular, allowing for future upgrades and the inclusion of new agent types as on-chain liquidity and trade complexity grow.
ParaSwap, now Velora, has processed over $100 billion in trading volume since its founding in 2019, and serves more than 4 million wallets, the release further stated.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44628685/bitcoin-is-a-realistic-global-reserve-asset-experts-say">Bitcoin Is A Realistic Global Reserve Asset, Experts Say</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Velora Rebrand Introduces Intents-Based Trading To Enhance DeFi Execution

Goldman Sachs analyst Alexander Blostein maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Buy and lowers the price target from $70 to $63.

Goldman Sachs Maintains Buy on TPG, Lowers Price Target to $63

Goldman Sachs analyst Mark Delaney maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Neutral and lowers the price target from $320 to $275.

TSLA

Goldman Sachs Maintains Neutral on Tesla, Lowers Price Target to $275

Goldman Sachs analyst Thiago Ojea maintains Ternium (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TX#NYSE">TX</a>) with a Buy and lowers the price target from $39 to $35.

Goldman Sachs Maintains Buy on Ternium, Lowers Price Target to $35

ALAB

AMAT

AOSL

CAMT

CRDO

INDI

MTSI

NVMI

ONTO

POWI

QCOM

QRVO

RGTI

RMBS

SITM

SLAB

SMTC

SYNA

TSEM

Shares of semiconductor companies are trading lower as markets react to President Trump's announcement of sweeping tariffs.

Goldman Sachs analyst Alexander Blostein maintains T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) with a Sell and lowers the price target from $103 to $89.

TROW

Goldman Sachs Maintains Sell on T. Rowe Price Group, Lowers Price Target to $89

Goldman Sachs analyst Alexander Blostein maintains Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) with a Neutral and lowers the price target from $121 to $105.

Goldman Sachs Maintains Neutral on Stifel Financial, Lowers Price Target to $105

Goldman Sachs analyst Alexander Blostein maintains Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) with a Buy and lowers the price target from $198 to $173.

Goldman Sachs Maintains Buy on Raymond James Finl, Lowers Price Target to $173

Analysts weigh in on the impact<a href="https://www.benzinga.com/25/04/44616760/donald-trump-sets-reciprocal-tariffs-on-key-trade-partners-in-historic-policy-shock"> newly imposed reciprocal tariffs</a> by President Donald Trump on other countries and the effect it could have on Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and its products, such as the iPhone.
The Apple Analysts: Rosenblatt analyst Barton Crockett maintained a Buy rating on Apple with a $263 price target.
Tigress Financial analyst Ivan Feinseth reiterated a Strong Buy rating on Apple and raised the price target from $295 to $300.
Read Also:<a href="https://www.benzinga.com/tech/25/03/44544129/exclusive-which-magnificent-7-stock-will-perform-best-in-the-next-3-months-new-poll-shows-a-favorite-and-its-not-nvidia"> EXCLUSIVE: Which Magnificent 7 Stock Will Perform Best In The Next 3 Months? New Poll Shows A Favorite (And It&#8217;s Not Nvidia)</a>
Rosenblatt on AAPL: American icon Apple could be severely impacted by the tariffs, Crockett said in a new investor note.
"Trump tariffs could blow up Apple," Crockett said.
The analyst said the quick math suggests Apple could face $39.5 billion of tariff costs.
"We believe that close to 100% of iPhones sold in the U.S. are made in China, 90% of Macs, 80% of iPads, 90% of Apple Watches and 35% of Airpods."
The analyst said these products are also made in Vietnam. Tariffs on China and Vietnam are 54% and 46%, respectively.
"This looks pretty tough."
Without Apple raising prices, the analyst estimates that operating profits and earnings per share could be down by around 32% annually. Raising prices could offset demand, the analyst warned.
"We note that Apple's main rival in the U.S., Samsung, is based in South Korea upon which Trump just levied 25% tariffs. So Samsung, as it stands now, could be meaningfully competitively advantaged, tariff-wise."
Crockett also questions if China will retaliate and try to hurt Apple in the country to help its own local smartphone makers.
The analyst said Apple moving iPhone production to the U.S. would be "hard to do economically" and can't happen for years.
Tigress on AAPL: Services growth and the integration of Apple Intelligence are future catalysts for Apple, Feinseth writes in a new investor note.
The analyst said these two items and Apple's growing customer base will "continue to drive ongoing revenue and cash flow growth."
"AAPL's ongoing integration of Apple Intelligence will increasingly enhance the cadence of new product introductions and drive Services growth and further growth of its ecosystem," Feinseth said.
Feinseth said Apple Intelligence will help grow new product sales and Services revenue in the future.
"Strength in Services revenue continues to be driven by expanded application and services with new offerings in Apple Arcade games and new programming on Fitness+."
The analyst highlighted Apple's installed base of active devices hitting an all-time high in the most recently reported quarter.
"AAPL remains a must-own stock driven by its industry leadership position and significant Economic Earnings power, brand equity, loyal customer base, cash generation ability, increasingly strong balance sheet, and ability to innovate to create new products as it expands its ecosystem."
AAPL Price Action: Apple stock is down 8.73% to $204.31 on Thursday at publication versus a 52-week trading range of $164.08 to $260.09. Apple stock is down 15.6% year-to-date in 2025.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/04/44629335/apple-stock-slammed-by-trump-tariffs-is-a-death-cross-next">Apple Stock Slammed By Trump Tariffs: Is A Death Cross Next?</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Reiteration

Global

Tech

'Trump Tariffs Could Blow Up Apple': Analyst Estimates $39.5 Billion Impact

Goldman Sachs analyst Michael Ng maintains Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) with a Buy and lowers the price target from $26 to $22.5.

Penguin Solutions, Inc. - Ordinary Shares

PENG

Goldman Sachs Maintains Buy on Penguin Solutions, Lowers Price Target to $22.5

Goldman Sachs analyst Alexander Blostein maintains Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) with a Buy and raises the price target from $40 to $44.

Goldman Sachs Maintains Buy on Marex Group, Raises Price Target to $44

BROS

CAVA

DASH

SBUX

SHAK

Shares of restaurant-related companies are trading lower as markets react to President Trump's announcement of sweeping tariffs.

Goldman Sachs analyst Alexander Blostein maintains Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) with a Neutral and lowers the price target from $47 to $41.

Janus Henderson Group plc Ordinary Shares

Goldman Sachs Maintains Neutral on Janus Henderson Group, Lowers Price Target to $41

Press Releases

GE Vernova Inc. (GEV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Legal

Contracts

Woodward Signs Agreement to Divest Its Heavy Duty Gas Turbines Combustion Parts Business Based in Greenville, S.C., to GE Vernova

GE Vernova raises multi-year financial outlook, initiates dividend and authorizes buyback

GE Vernova declares $0.25 per share quarterly dividend and initial $6 billion share buyback

Engine No. 1, Chevron, and GE Vernova to Power U.S. Data Centers

GE Vernova to Invest Almost $600 Million in U.S. Factories and Facilities Over Next Two Years

NRG Energy, GE Vernova and Kiewit Accelerating New Generation Capacity to Support Demand Growth

PyroGenesis and GE Vernova Sign Memorandum of Understanding (MOU)

Homer City Redevelopment and Kiewit Announce Country's Largest Natural Gas-Powered Data Center Campus to Support AI and HPC Demand

PYRGF

TSX:PYR

Bloom Energy Corporation Class A Common Stock

Bloom Energy

Babcock & Wilcox Enterprises, Inc. Common Stock

Babcock & Wilcox

Broadwind

Clean Energy Technologies, Inc. - Common Stock

Clean Energy Technologies

Nano Nuclear Energy

NET Power

Energy Vault Holdings

Ocean Power Technologies, Inc. Common Stock

Ocean Power Techs

Polar Power

Pioneer Power Solutions, Inc. - Common Stock

Pioneer Power Solutions

Power Solutions International, Inc. - Common Stock

Power Solutions Intl

NuScale Power Corporation Class A Common Stock

NuScale Power

TPI Composites

Susquehanna

Jefferies

RBC Capital

Guggenheim

BMO Capital

GE Vernova Inc. Common Stock

ACHR

ACVA

AMPX

AMSC

AMTM

APWC

AVAV

AXON

AZEK

BYRN

EFOI

Shares of companies within the broader industrial sector are trading lower as markets react to President Trump's announcement of sweeping tariffs.

Comments

GE Vernova

空売り

GE Vernova (NYSE:GEV) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル